NCT00325715

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Conditions

• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	AGN 201904
DRUG	esomeprazole

Timeline

• Start date: 2006-04-01
• Primary completion: 2006-08-01
• Completion: 2006-08-01
• First posted: 2006-05-15
• Last updated: 2011-06-02

Locations

1 site across 1 country: United States